Accentia Biopharmaceuticals, Inc.
324 South Hyde Park Avenue
Suite 350
Tampa,
FL 33606
United States - Map
Phone: 813-864-2554
Fax: 813-258-6912
Web Site: http://www.accentia.net
| Accentia Biopharmaceuticals, Inc., a biopharmaceutical company, together with its subsidiaries, develops and commercializes drug candidates that are in late-stage clinical development based on active pharmaceutical ingredients in the therapeutic areas of respiratory disease and oncology. It operates in two segments: Biopharmaceutical Products and Services, and Specialty Pharmaceuticals. The Biopharmaceutical Products and Services segment develops late-stage biopharmaceutical products. Its products, which are under Phase III clinical trials, include SinuNase for the treatment of chronic rhinosinusitis; BiovaxID, a patient-specific anti-cancer vaccine focusing on the treatment of follicular non-Hodgkins lymphoma; and Revimmune for the treatment of multiple sclerosis, an autoimmune disease that affects the central nervous system, and various autoimmune diseases, including systemic lupus, myasthenia gravis, and aplastic anemia. This segment also provides various consulting services relating to biopharmaceutical product development; and engages in the production of custom biologic products and cell culture instruments and systems for biopharmaceutical and biotechnology companies, medical schools, universities, hospitals, and research institutions. The Specialty Pharmaceuticals segment markets and sells pharmaceutical products that are developed primarily by third-party development partners. Its products comprise Respi-TANN, a prescription antitussive decongestant for temporary relief of cough and nasal congestion; SinuTest, a test used in connection with the diagnosis of chronic sinusitis; and Zinotic, a treatment of superficial infections of the external ear. This segment’s products under development include AllerNase, a formulated suspension of an intranasal topical steroid indicated for the treatment of allergic and non-allergic rhinitis; and Emezine, a product for control of nausea and vomiting. The company was founded in 2002 and is headquartered in Tampa, Florida. |
|
| Key Statistics |
| |
| | Pay | Exercised | Dr. Francis E. O'Donnell Jr.,
Chairman and Chief Exec. Officer |
N/A
| N/A | Mr. Alan M. Pearce , 59
Chief Financial Officer, Principal Accounting Officer |
$
285.00K | N/A | Dr. Steven R. Arikian M.D., 50
Director, Pres of Biopharmaceutical Products & Services and Chief Operating Officer of Biopharmaceutical Products & Services |
N/A
| N/A | Mr. James A. McNulty CPA,
Sec. and Treasurer |
$
159.00K | N/A | Mr. Samuel S. Duffey J.D.,
Gen. Counsel |
N/A
| N/A |
|
|
|
Dollar amounts are as of
31-Dec-07
and compensation values are for the last fiscal
year ending on that date. "Pay" is salary, bonuses, etc. "Exercised" is the value of
options exercised during the fiscal year.
| |
|
1.49% Nasdaq 
0.27%
Profile
